- Home
- NBP vs RNA Comparison
NBP vs RNA Comparison
Compare NBP & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBP | RNA |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.2M | 226.3M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | NBP | RNA |
|---|---|---|
| Price | $1.77 | $13.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $9.00 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 1.2M | 163.0K |
| Earning Date | 04-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | N/A | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.67 | $11.95 |
| 52 Week High | $5.19 | $73.06 |
Technical Indicators
Market Signals| Indicator | NBP | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 25.14 | 41.81 |
| Support Level | N/A | $13.06 |
| Resistance Level | $2.73 | $13.97 |
| Average True Range (ATR) | 0.12 | 0.47 |
| MACD | -0.03 | 0.29 |
| Stochastic Oscillator | 10.67 | 49.26 |
Price Performance
Historical ComparisonAbout NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.